RT Journal Article
SR Electronic
T1 Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.14.20248137
DO 10.1101/2020.12.14.20248137
A1 Follmann, Dean
A1 Fintzi, Jonathan
A1 Fay, Michael P.
A1 Janes, Holly E.
A1 Baden, Lindsey
A1 Sahly, Hana El
A1 Fleming, Thomas R.
A1 Mehrotra, Devan V.
A1 Carpp, Lindsay N.
A1 Juraska, Michal
A1 Benkeser, David
A1 Donnell, Deborah
A1 Fong, Youyi
A1 Han, Shu
A1 Hirsch, Ian
A1 Huang, Ying
A1 Huang, Yunda
A1 Hyrien, Ollivier
A1 Luedtke, Alex
A1 Carone, Marco
A1 Nason, Martha
A1 Vandebosch, An
A1 Zhou, Honghong
A1 Cho, Iksung
A1 Gabriel, Erin
A1 Kublin, James G.
A1 Cohen, Myron S.
A1 Corey, Lawrence
A1 Gilbert, Peter B.
A1 Neuzil, Kathleen M.
YR 2020
UL http://medrxiv.org/content/early/2020/12/14/2020.12.14.20248137.abstract
AB Background Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occur before long-term efficacy and safety are known.Methods Following vaccination of the placebo group, we show that placebo-controlled vaccine efficacy can be derived by assuming the benefit of vaccination over time has the same profile for the original vaccine recipients and the placebo crossovers. This reconstruction allows estimation of both vaccine durability and potential vaccine-associated enhanced disease.Results Post-crossover estimates of vaccine efficacy can provide insights about durability, identify waning efficacy, and identify late enhancement of disease, but are less reliable estimates than those obtained by a standard trial where the placebo cohort is maintained. As vaccine efficacy estimates for post-crossover periods depend on prior vaccine efficacy estimates, longer pre-crossover periods with higher case counts provide better estimates of late vaccine efficacy. Further, open-label crossover may lead to riskier behavior in the immediate crossover period for the unblinded vaccine arm, confounding vaccine efficacy estimates for all post-crossover periods.Conclusions We advocate blinded crossover and continued follow-up of trial participants to best assess vaccine durability and potential delayed enhancement of disease. This approach allows placebo recipients timely access to the vaccine when it would no longer be proper to maintain participants on placebo, yet still allows important insights about immunological and clinical effectiveness over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, through grant numbers UM1AI068635, R37AI054165, UM1AI068617, UM1Al148684, and R37-AI29168. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are included within the manuscript and its appendix.